Role of Glutamine as Myocardial Protector in Elective On-Pump CABG Surgery With Low EF

Last updated: November 9, 2023
Sponsor: National Cardiovascular Center Harapan Kita Hospital Indonesia
Overall Status: Completed

Phase

3

Condition

Chest Pain

Coronary Artery Disease

Thrombosis

Treatment

Placebo

L-alanyl-L-glutamine dipeptide

Clinical Study ID

NCT04560309
LB.02.01/VII/466/KEP059/202
LB.02.01/VII/466/KEP059/202
  • Ages > 18
  • All Genders

Study Summary

Coronary artery disease has the highest mortality rate worldwide and coronary artery bypass grafting (CABG) is the most common cardiac surgery performed in patients with coronary artery disease to revascularize the heart. Despite of improvement in operation techniques, cardioplegia, cardiopulmonary bypass (CPB), myocardial injury related to on-pump CABG is still prominent. In patient with low ejection fraction undergone on-pump CABG, myocardial injury is related to worse outcome and prognosis during peri-operative and post-operative period. On-pump CABG patients with low ejection fraction has increased (up to four times higher) post-operative in hospital mortality rate compared to patient with normal ejection fraction. Administration of intravenous glutamine had been documented in reducing myocardial damage during cardiac surgery and previous studies indicated that glutamine can protect against myocardial injury by various mechanism during ischemia and reperfusion. The purpose of this study to determine whether intravenous glutamine could prevent the decline of plasma glutamine level, reduce myocardial damage, improve hemodynamic profile, and reduce morbidity of on-pump CABG in patients with low ejection fraction.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with coronary heart disease indicated for elective coronary artery bypassgrafting under cardiopulmonary bypass
  • Patients with left ventricle ejection fraction 31% -50% confirmed by echocardiographyor radio nuclear study.
  • Patients age ≥18 years
  • Never had heart surgery before
  • Agree to participate in the study and signed informed consent

Exclusion

Exclusion Criteria:

  • Emergency coronary artery grafting bypass
  • Having additional procedures other than coronary artery bypass grafting
  • History of myocardial infarction with onset less than 3 months
  • Patients with serum creatinine level more than 2 g/dL
  • Patients with ALT/AST levels more than 1.5 times the upper limit of normal value
  • Required to use intra-aortic balloon pump pre-operatively
  • History of stroke with onset less than 3 months
  • History of pre-operative atrial fibrillation
  • History of heart conduction problem and/or using a pacemaker
  • Patients with HIV
  • Contraindications to pulmonary artery catheter insertion Drop out Criteria
  • Experiencing stroke after surgery
  • Experiencing surgery related complication (haemorrhage) requiring re operation
  • Requiring continuous veno-venous hemofiltration or haemodialysis after surgery
  • Delayed sternal closure
  • Aortic cross clamp duration more than 120 minutes and/or cardiopulmonary bypass timemore than 180 minutes

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 3
Study Start date:
January 01, 2021
Estimated Completion Date:
November 23, 2021

Study Description

The study was a double-blind randomized controlled trial to assess the role of glutamine as a myocardial protection during coronary artery bypass grafting under cardiopulmonary bypass in patients with left ventricle ejection fraction of 31-50%. This study was approved by Institutional Review Board of National Cardiovascular Center Harapan Kita and informed consent was obtained before randomization for patient eligible for this study. Allocation of participant to the treatment group was done by block randomization by staff who was not involved in the study. The intervention drug was prepared by pharmacist who also was not involved in the study. Glutamine solution was supplied as L-alanyl-L-glutamine dipeptide (Dipeptiven, 200 mg/mL, Fresenius Kabi, Bad Homburg, Germany) and was prepared to contain 0.5gr/kgbw glutamine diluted in NaCl 0.9% to a final volume of 500 mL. Placebo was supplied as 500 ml of NaCl 0.9%, prepared in similar fashion and packaging as glutamine solution. Principal investigator, care provider, outcome assessor, and participant were blinded to the assigned group until after the end of the study.

Baseline participant characteristics were collected before the intervention included age, sex, body weight, body height, body mass index, and documented pre-operative left ventricle ejection fraction. Coronary artery bypass grafting and cardiopulmonary bypass was done in concordance to standard operating procedure in National Cardiovascular Center Harapan Kita, followed by transit time flow meter measurement to ensure quality of the graft. Modifying factor of the study, the investigators measured duration of surgery, duration of cardiopulmonary bypass, and duration of aortic cross clamp.

The primary outcome of the study was plasma troponin I level. The investigators anticipated plasma troponin I level difference of 20% with standard deviation of 0.04 ng/mL, and for statistical power of 80% and level of significance of 0.05, the required sample size was 24.5 participants per group. As anticipation for participant drop out, the investigators planned to recruit a total of 60 participants.

Connect with a study center

  • National Cardiovascular Center Harapan Kita Hospital Indonesia

    Jakarta, 11420
    Indonesia

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.